Get the Stockscreener App
20.35
4.41%
0.86
After Hours:
20.58
0.23
+1.13%
Tonix Pharmaceuticals Holding Corp stock is traded at $20.35, with a volume of 889.50K.
It is up +4.41% in the last 24 hours and down -15.94% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$19.49
Open:
$19.57
24h Volume:
889.50K
Relative Volume:
0.64
Market Cap:
$178.39M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-1.8073
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
+2.57%
1M Performance:
-15.94%
6M Performance:
+14.20%
1Y Performance:
+22.96%
1-Day Range:
$19.57
$20.58
1-Week Range:
$18.53
$20.58
52-Week Range:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
20.35 | 170.85M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.17 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
478.58 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.31 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
829.83 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.02 | 33.75B | 398.11M | -1.03B | -868.57M | -5.7032 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix’s fibromyalgia drug shows significant pain reduction in study - Investing.com
How to recover losses in Tonix Pharmaceuticals Holding Corp. stockTrade Exit Report & Low Drawdown Trading Strategies - newser.com
Sentiment analysis tools applied to Tonix Pharmaceuticals Holding Corp.July 2025 PostEarnings & Stepwise Swing Trade Plans - newser.com
Tonix’s fibromyalgia drug shows significant pain reduction in study By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Unveils Positive Trial Results for Tonmya - GuruFocus
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence - The Manila Times
Tonix PharmaceuticalsPrelim Q3 net revenue from product sales $3.3 millionSEC filing - MarketScreener
Tonix (Nasdaq: TNXP) reports Phase 3 Tonmya fibromyalgia data: Week 14 pain reduction - Stock Titan
Is Tonix Pharmaceuticals Holding Corp. stock a safe haven assetEarnings Overview Summary & Low Risk High Reward Ideas - newser.com
Is Tonix Pharmaceuticals Holding Corp. stock trading at a premium valuation2025 Institutional Moves & Weekly Breakout Watchlists - newser.com
Tonix Pharmaceuticals Holding Corp. stock trend forecast2025 Volatility Report & Short-Term Trading Alerts - newser.com
First patient dosed in MGH-Led FOCUS study of Tonix’s investigational intranasal Oxytocin product - Proactive financial news
Understanding Momentum Shifts in (TNXP) - news.stocktradersdaily.com
Tonix: Assessing Tonmya's Commercial Potential Ahead Of Q4 2025 Launch - Seeking Alpha
Tonix Pharmaceuticals (TNXP) Launches New Study for Rare Endocri - GuruFocus
Can Tonix Pharmaceuticals Holding Corp. recover in the next quarterPortfolio Risk Report & Real-Time Volume Spike Alerts - newser.com
Tonix (Nasdaq: TNXP) doses first patient in MGH FOCUS AVP-D study testing 6 IU and 24 IU - Stock Titan
Tonix Pharmaceuticals Holding Corp. stock daily chart insightsTrade Risk Report & Daily Price Action Insights - newser.com
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence - The Manila Times
Tonix Pharmaceuticals Announces Poster Presentation of Tonmya™ at 2025 American College of Rheumatology Convergence - Quiver Quantitative
What analysts say about Tonix Pharmaceuticals Holding Corp stockSmall Cap Stock Opportunities & Small Investment Trading Growth - earlytimes.in
Analyzing Tonix Pharmaceuticals Holding Corp. with risk reward ratio chartsMarket Volume Summary & AI Driven Stock Movement Reports - newser.com
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
2.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):